my country's new crown special medicine may be a "dark horse" to prevent mutant strains!

One injection of 0.

In Beijing Ditan Hospital, patients infected with the new crown received "compassionate medication" called DXP-604, which was independently developed by China

The first-line clinical performance makes DXP-604 expected to become the "dark horse" of the new crown specific drug.

The drug was jointly developed by the team of Peking University Xie Xiaoliang and Danxu Biology

What does the new crown medicine look like?

DXP-604 is a neutralizing antibody drug, and its prototype is the neutralizing antibody that exists in the human body

This step is considered "sea selection", and the special medicine is among them

As a pioneer of single-cell genomics, Xie Xiaoliang's laboratory has leading international technical advantages

The Peking University team screened more than 8,000 candidate antibodies in just a few months

That's why the drug only needs 0.

How to prevent the virus from escaping?

The research and development of new crown special drugs is changing rapidly! In the past 22 months, global resources have been rapidly gathered; in the past few months, a large number of drug candidates have suffered "broken down" due to frequent mutation of the virus

The repeated and complex COVID-19 epidemic has put forward higher requirements for new crown specific drugs to deal with mutations

"We had a candidate drug DXP-593 that was escaped by the delta strain

Escape is costly

what to do? Xie Xiaoliang's team originally planned to combine DXP-593 with DXP-604, but a new research method brought unexpected surprises.

"We have recently developed a high-throughput yeast display technology to test all the more than 4,000 possible single-point mutations in the receptor binding domain of the new coronavirus protein (S protein) with neutralizing antibodies one by one

The "escapes" that appear in the real world have been verified one by one.

The test results of DXP-604 were unexpected.
It gave the new coronavirus a "dilemma": either it does not mutate, it is neutralized by DXP-604, or it mutates "out of the circle", but it will change so much that it is difficult to combine it again.
on human cells
.
It is the "killer" of DXP-604 to let the new crown virus fall into the situation of "unchanged waiting for death, change is courting death"
.

In order to verify the results, the team also cooperated with a third-party team to use the fake virus platform to do a real "battle" of mutation escape, and the results were consistent
.

What is the launch plan of Super antibody?

"It's the Super Antibody we're looking for
.
" Looking back at the twists and turns along the way, Xie Xiaoliang concluded that antibody specific drugs are not all-round, the more "strong" the better, too strong will make the virus mutate and regenerate, and DXP-604 is competing The location is just right, and in the end it is "Tai Chi" to let the virus die from nowhere
.

"We have a full-spectrum antibody that can resist single point mutations in all RBD regions, which is sufficient to neutralize all existing mutant strains, and will not be escaped by future mutant strains to the greatest extent
.
" Xie Xiaoliang said
.

Regarding the clinical trial and listing schedule of DXP-604, Xie Xiaoliang introduced that the domestic phase II clinical trial is being carried out, and has contacted Sinopharm Group China Bio to advance the overseas phase II/III clinical trial
.
Beijing has approved DXP-604 as a "compassionate medication" for clinical treatment in Beijing Ditan Hospital.
Currently, both clinical trials and "compassionate medication" drugs are produced by WuXi Biologics
.
Xie Xiaoliang expressed the hope that China's self-developed new crown special drugs will be available as soon as possible
.